Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 442

1.

A prospective targeted serum metabolomics study of pancreatic cancer in postmenopausal women.

Jiao L, Maity S, Coarfa C, Rajapakshe K, Chen L, Jin F, Putluri V, Tinker LF, Mo Q, Chen F, Sen S, Sangi-Haghpeykar H, El-Serag HB, Putluri N.

Cancer Prev Res (Phila). 2019 Feb 5. pii: canprevres.0201.2018. doi: 10.1158/1940-6207.CAPR-18-0201. [Epub ahead of print]

PMID:
30723176
2.

Reply to Letter to the Editor regarding the Houston Consensus conference on testing for H. pylori infection in the United States.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2019 Jan 30. pii: S1542-3565(19)30086-2. doi: 10.1016/j.cgh.2019.01.039. [Epub ahead of print] No abstract available.

PMID:
30710706
3.

Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study.

Feng Z, Marrero JA, Khaderi S, Singal AG, Kanwal F, Loo N, Beretta L, Ning J, El-Serag HB.

Am J Gastroenterol. 2019 Jan 23. doi: 10.14309/ajg.0000000000000068. [Epub ahead of print]

PMID:
30699099
4.

Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization.

Tansel A, Kramer J, Feng H, El-Serag HB, Kanwal F.

Dig Dis Sci. 2019 Jan 23. doi: 10.1007/s10620-019-5459-3. [Epub ahead of print]

PMID:
30673983
5.

Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].

Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY.

J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32629-1. doi: 10.1016/j.jhep.2018.12.010. [Epub ahead of print] No abstract available.

PMID:
30635242
6.

Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey.

Kim HS, Yang JD, El-Serag HB, Kanwal F.

J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13060. [Epub ahead of print]

PMID:
30629790
7.

Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality.

Thrift AP, Natarajan Y, Liu Y, El-Serag HB.

Clin Gastroenterol Hepatol. 2019 Jan 6. pii: S1542-3565(19)30019-9. doi: 10.1016/j.cgh.2018.12.046. [Epub ahead of print]

PMID:
30625400
8.

Traditional Chinese Medicine to the rescue of allopathic medicine in the co-adjuvant treatment of hepatocellular carcinoma.

Sparkman J, Hernaez R, El-Serag HB.

Transl Gastroenterol Hepatol. 2018 Nov 26;3:97. doi: 10.21037/tgh.2018.11.05. eCollection 2018. No abstract available.

9.

Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure.

Hernaez R, Kramer JR, Liu Y, Tansel A, Natarajan Y, Hussain KB, Ginès P, Solà E, Moreau R, Gerbes A, El-Serag HB, Kanwal F.

J Hepatol. 2018 Dec 25. pii: S0168-8278(18)32637-0. doi: 10.1016/j.jhep.2018.12.018. [Epub ahead of print]

PMID:
30590100
10.

Validation of the Hepatocellular Carcinoma Early detection Screening (HES) algorithm in a Cohort of Veterans with Cirrhosis.

Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB.

Clin Gastroenterol Hepatol. 2018 Dec 14. pii: S1542-3565(18)31378-8. doi: 10.1016/j.cgh.2018.12.005. [Epub ahead of print]

PMID:
30557738
11.

Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or Associated With Nonadherence) Identify Possible Health Care System Quality Measures.

Tau A, Bernica J, Thrift AP, El-Serag HB.

Gastroenterology. 2019 Feb;156(3):809-811. doi: 10.1053/j.gastro.2018.10.035. Epub 2018 Oct 25. No abstract available.

PMID:
30514636
12.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):2005-2006. doi: 10.1016/j.cgh.2018.08.035. No abstract available.

PMID:
30454939
13.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):2004. doi: 10.1016/j.cgh.2018.08.031. No abstract available.

PMID:
30454938
14.

Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma.

Hammad TA, Thrift AP, El-Serag HB, Husain NS.

Dig Dis Sci. 2019 Feb;64(2):367-372. doi: 10.1007/s10620-018-5336-5. Epub 2018 Oct 28.

PMID:
30370493
15.

Epidemiology and Management of Hepatocellular Carcinoma.

Kulik L, El-Serag HB.

Gastroenterology. 2019 Jan;156(2):477-491.e1. doi: 10.1053/j.gastro.2018.08.065. Epub 2018 Oct 24. Review.

PMID:
30367835
16.

Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection.

Thrift AP, Liu Y, Tsavachidis S, White DL, El-Serag HB.

Clin Gastroenterol Hepatol. 2018 Oct 18. pii: S1542-3565(18)31145-5. doi: 10.1016/j.cgh.2018.10.024. [Epub ahead of print]

PMID:
30342914
17.

Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin.

Husain NS, El-Serag HB.

Nat Rev Clin Oncol. 2018 Dec;15(12):728-730. doi: 10.1038/s41571-018-0096-x. No abstract available.

PMID:
30237519
18.

Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, Li L, Desiderio R, Thrift AP, Asch SM, Chu J, El-Serag HB.

Gastroenterology. 2018 Dec;155(6):1828-1837.e2. doi: 10.1053/j.gastro.2018.08.024. Epub 2018 Aug 23.

PMID:
30144434
19.

Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival.

Wenker TN, Tan MC, Liu Y, El-Serag HB, Thrift AP.

Dig Dis Sci. 2018 Nov;63(11):3112-3119. doi: 10.1007/s10620-018-5241-y. Epub 2018 Aug 14.

PMID:
30109579
20.

Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBPα-p300 Axis.

Nguyen P, Valanejad L, Cast A, Wright M, Garcia JM, El-Serag HB, Karns R, Timchenko NA.

Cell Rep. 2018 Aug 7;24(6):1597-1609. doi: 10.1016/j.celrep.2018.07.014.

21.

Hospitalizations for Chronic Liver Disease: Time to Intervene at Multiple Levels.

El-Serag HB.

Gastroenterology. 2018 Sep;155(3):607-609. doi: 10.1053/j.gastro.2018.07.036. Epub 2018 Aug 1. No abstract available.

22.

Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women's Health Initiative Study.

Wang Z, White DL, Hoogeveen R, Chen L, Whitsel EA, Richardson PA, Virani SS, Garcia JM, El-Serag HB, Jiao L.

J Clin Med. 2018 Aug 2;7(8). pii: E197. doi: 10.3390/jcm7080197.

23.

Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study.

Dong J, Gu X, El-Serag HB, Thrift AP.

Clin Gastroenterol Hepatol. 2018 Jul 20. pii: S1542-3565(18)30742-0. doi: 10.1016/j.cgh.2018.07.018. [Epub ahead of print]

PMID:
30036643
24.

Long-term follow up of patients with obscure gastrointestinal bleeding examined with video capsule endoscopy.

Sealock RJ, Thrift AP, El-Serag HB, Sellin J.

Medicine (Baltimore). 2018 Jul;97(29):e11429. doi: 10.1097/MD.0000000000011429.

25.

Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.

Tan MC, El-Serag HB, Yu X, Thrift AP.

Aliment Pharmacol Ther. 2018 Aug;48(4):469-477. doi: 10.1111/apt.14895. Epub 2018 Jun 29.

PMID:
29956826
26.

The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans.

Nguyen T, Khan A, Liu Y, El-Serag HB, Thrift AP.

Am J Gastroenterol. 2018 Sep;113(9):1310. doi: 10.1038/s41395-018-0169-6. Epub 2018 Jun 27.

PMID:
29946180
27.

Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation.

Tan MC, Kanthasamy KA, Yeh AG, Kil D, Pompeii L, Yu X, El-Serag HB, Thrift AP.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):65-72.e5. doi: 10.1016/j.cgh.2018.05.042. Epub 2018 Jun 11.

PMID:
29902646
28.

Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium.

Wang Z, Shaheen NJ, Whiteman DC, Anderson LA, Vaughan TL, Corley DA, El-Serag HB, Rubenstein JH, Thrift AP.

Am J Gastroenterol. 2018 Aug;113(8):1148-1155. doi: 10.1038/s41395-018-0070-3. Epub 2018 Jun 8.

PMID:
29880962
29.

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.

Kramer JR, Puenpatom A, Erickson KF, Cao Y, Smith D, El-Serag HB, Kanwal F.

J Viral Hepat. 2018 Nov;25(11):1270-1279. doi: 10.1111/jvh.12937. Epub 2018 Jul 3.

PMID:
29851265
30.

A Systematic Review of the Effectiveness of Psychological Treatments for IBS in Gastroenterology Settings: Promising but in Need of Further Study.

Thakur ER, Shapiro J, Chan J, Lumley MA, Cully JA, Bradford A, El-Serag HB.

Dig Dis Sci. 2018 May 10. doi: 10.1007/s10620-018-5095-3. [Epub ahead of print] Review.

PMID:
29744772
31.

How we approach it: treatment options for hepatocellular carcinoma.

Hernaez R, El-Serag HB.

Am J Gastroenterol. 2018 Jun;113(6):791-794. doi: 10.1038/s41395-018-0008-9. Epub 2018 May 1. No abstract available.

PMID:
29713029
32.

Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis.

Wang Z, Graham DY, Khan A, Balakrishnan M, Abrams HR, El-Serag HB, Thrift AP.

Int J Epidemiol. 2018 Apr 16. doi: 10.1093/ije/dyy055. [Epub ahead of print]

PMID:
29672681
33.

Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.

Shah R, Ho EY, Kramer JR, Richardson P, Sansgiry S, El-Serag HB, Hou JK.

Dig Dis Sci. 2018 Jun;63(6):1551-1557. doi: 10.1007/s10620-018-5042-3. Epub 2018 Apr 16.

PMID:
29663266
34.

A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women.

White DL, Hoogeveen RC, Chen L, Richardson P, Ravishankar M, Shah P, Tinker L, Rohan T, Whitsel EA, El-Serag HB, Jiao L.

Cancer Med. 2018 May;7(5):2180-2191. doi: 10.1002/cam4.1426. Epub 2018 Mar 23.

35.

Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States.

El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe S, Elfant A, Haas T, Hapke RJ, Graham DY.

Clin Gastroenterol Hepatol. 2018 Jul;16(7):992-1002.e6. doi: 10.1016/j.cgh.2018.03.013. Epub 2018 Mar 17. Erratum in: Clin Gastroenterol Hepatol. 2019 Feb 2;:.

PMID:
29559361
36.

Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.

Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY.

J Hepatol. 2018 Aug;69(2):278-285. doi: 10.1016/j.jhep.2018.02.032. Epub 2018 Mar 16. Erratum in: J Hepatol. 2019 Jan 8;:.

PMID:
29551708
37.

Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population.

Zou WY, El-Serag HB, Sada YH, Temple SL, Sansgiry S, Kanwal F, Davila JA.

Dig Dis Sci. 2018 May;63(5):1173-1181. doi: 10.1007/s10620-018-4989-4. Epub 2018 Mar 5.

PMID:
29508165
38.

Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications.

Mapakshi S, Kramer JR, Richardson P, El-Serag HB, Kanwal F.

Clin Gastroenterol Hepatol. 2018 Oct;16(10):1677-1678. doi: 10.1016/j.cgh.2018.01.042. Epub 2018 Feb 1.

PMID:
29410051
39.

Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis.

Vanga RR, Tansel A, Sidiq S, El-Serag HB, Othman MO.

Clin Gastroenterol Hepatol. 2018 Aug;16(8):1220-1228.e4. doi: 10.1016/j.cgh.2018.01.027. Epub 2018 Jan 31. Review.

PMID:
29374614
40.

Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis.

Hernaez R, Kanwal F, El-Serag HB.

Hepatology. 2018 Jul;68(1):7-9. doi: 10.1002/hep.29776. Epub 2018 May 10. No abstract available.

PMID:
29315712
41.

Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis?

Balakrishnan M, El-Serag HB.

Aliment Pharmacol Ther. 2018 Feb;47(3):437-438. doi: 10.1111/apt.14464. No abstract available.

42.

Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection.

Bhakta D, Graham DY, Chan J, El-Serag HB.

Clin Gastroenterol Hepatol. 2018 Sep;16(9):1531-1532. doi: 10.1016/j.cgh.2017.12.040. Epub 2018 Jan 3. No abstract available.

PMID:
29306045
43.

Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.

Tayob N, Richardson P, White DL, Yu X, Davila JA, Kanwal F, Feng Z, El-Serag HB.

BMC Med Res Methodol. 2018 Jan 4;18(1):1. doi: 10.1186/s12874-017-0458-6.

44.

Current Status of Sorafenib Use for Treatment of Hepatocellular Carcinoma.

El-Serag HB, Margaret M, Alkek AB.

Gastroenterol Hepatol (N Y). 2017 Oct;13(10):623-625. No abstract available.

45.

Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.

Hsu YC, Ho HJ, Lee TY, Huang YT, Wu MS, Lin JT, Wu CY, El-Serag HB.

J Viral Hepat. 2018 May;25(5):543-551. doi: 10.1111/jvh.12832. Epub 2018 Mar 30.

PMID:
29193536
46.

Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease.

Kaur M, Singapura P, Kalakota N, Cruz G, Shukla R, Ahsan S, Tansel A, Thrift AP, El-Serag HB.

Clin Gastroenterol Hepatol. 2018 Oct;16(10):1616-1621.e1. doi: 10.1016/j.cgh.2017.11.038. Epub 2017 Nov 23.

PMID:
29175527
47.

Advances in the management of hepatocellular carcinoma.

El-Serag HB.

Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):2-6. No abstract available.

PMID:
29036036
48.

The treatment path in hepatocellular carcinoma.

El-Serag HB, Zhu AX, Johnson MS.

Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):1-20.

PMID:
29036035
49.

Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Massarweh NN, El-Serag HB.

Cancer Control. 2017 Jul-Sep;24(3):1073274817729245. doi: 10.1177/1073274817729245. Review.

50.

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.

Lin M, Kramer J, White D, Cao Y, Tavakoli-Tabasi S, Madu S, Smith D, Asch SM, El-Serag HB, Kanwal F.

Aliment Pharmacol Ther. 2017 Nov;46(10):992-1000. doi: 10.1111/apt.14328. Epub 2017 Sep 26.

Supplemental Content

Loading ...
Support Center